Summary
60 / 100 · Bulios Score
What speaks for it
- Out of every 100 INR of revenue, 17 INR is left as net profit.
- It could repay all its net debt from 0.0 years of operating profit.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue fell by 4.7% a year over the last 3 years.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 16.2 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (INR)
Diluted EPS (INR)
Revenue grew by 1.8% a year over 5 years. Over the last 3 years it fell by 4.7% a year.
Growth in detailDoes it make money?
Very wellWhere 100 INR of revenue goes
- Cost of sales 73 INR
- Sales and administration 10 INR
- Taxes and other 0.3 INR
- Net profit 17 INR
Net profit, industry median (Chemicals - Specialty) 6.1 INR
Out of every 100 INR of revenue, 17 INR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.58%
- Paid out of profit
- 9.4%
You receive ₹0.50 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail